ArticleJournal of gastrointestinal oncology2026
Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization (TACE) combined with molecular targeted agents (MTAs) and/or immune checkpoint inhibitors (ICIs) has been increasingly used in patients with unresectable hepatocellular carcinoma (uHCC). However, the efficacy differences among these combination regimens have not been systematically compared. This study aimed to compare the efficacy of these treatment strategies and provide evidence for optimizing combination therapies in clinical practice. Methods: PubMed, Embase, the Cochrane Library, and Web of Science were systematically searched up to February 26, 2026. Randomized controlled trials (RCTs) and cohort studies involving patients with uHCC were included. The interventions were TACE combined with MTAs and/or ICIs. The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes were objective response rate (ORR) and disease control rate (DCR). A frequentist network meta-analysis (NMA) with a random-effects model was performed, and treatment regimens were ranked using P-scores. This NMA was registered in PROSPERO (CRD420261350164). Results: A total of 108 studies involving 19,761 patients and 26 treatment regimens were included, comprising 84 retrospective cohort studies and 24 RCTs. Compared with TACE alone, most combination regimens significantly improved patient outcomes. For OS, TACE + anlotinib + sintilimab (TACE + Anl + Sin), TACE + donafenib + toripalimab (TACE + Don + Tor), TACE + lenvatinib + tislelizumab (TACE + Len + Tis), TACE + sorafenib + camrelizumab (TACE + Sor + Cam), and TACE + apatinib + camrelizumab (TACE + Apa + Cam) were all significantly superior to TACE alone. P-score ranking showed that TACE + Anl + Sin was most likely to achieve the best OS outcome. For PFS, compared with TACE alone, TACE + Anl + Sin, TACE + Don + Tor, TACE + lenvatinib + pembrolizumab (TACE + Len + Pem), TACE + Len + Tis, and TACE + Apa + Cam significantly prolonged PFS. Among them, TACE + Len + Pem still showed strong benefit when compared with some triple-combination regimens and ranked first by P-score. For ORR, TACE + Len + Cam, TACE + Len + Tis, TACE + Anl + Sin, and TACE + Don + Tor all significantly improved ORR compared with TACE alone. Among these, TACE + Len + Cam had the highest P-score. For DCR, TACE + Len + Tis showed the best performance, while TACE + atezolizumab + bevacizumab (TACE + Ate + Bev), TACE + Anl + Sin, and TACE + Apa + Cam also demonstrated relatively high DCR. Conclusions: Compared with TACE alone, TACE combined with MTAs and ICIs can significantly improve outcomes in patients with uHCC. TACE + Anl + Sin, TACE + Len + Tis, and TACE + Apa + Cam may be promising treatment options, although more prospective studies are needed for further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.